Evidence map›Paper›PMID 40894008›Full record

ArticleResearch square2025

Oncogenic virus hijacks SOX18 pioneer function to enhance viral persistence.

Krista Tuohinto, Matthew S Graus, Peyton Staab, Ville Tiusanen, Fei Liangru, Susav Pradhan, Yew Yan Wong, Simon Weissmann, Jieqiong Lou, Elizabeth Hinde and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Krista TuohintoTranslational Cancer Medicine Research Program, University of Helsinki, Finland.
Matthew S GrausThe University of Sydney, School of Medical Sciences, Sydney, New South Wales, 2006, Australia.ORCID 0000-0001-5470-4837
Peyton StaabTranslational Cancer Medicine Research Program, University of Helsinki, Finland.
Ville TiusanenApplied Tumor Genomics Research Program, University of Helsinki, Finland.ORCID 0009-0002-9681-9696
Fei LiangruNorwegian Center for Molecular Biosciences and Medicine, University of Oslo, Norway.
Susav PradhanThe University of Sydney, School of Medical Sciences, Sydney, New South Wales, 2006, Australia.
Yew Yan WongThe University of Sydney, School of Medical Sciences, Sydney, New South Wales, 2006, Australia.
Simon WeissmannLeibniz Institute of Virology, Germany.
Jieqiong LouThe University of Melbourne, School of Physics, Melbourne, Victoria, 3010, Australia.
Elizabeth HindeThe University of Melbourne, School of Physics, Melbourne, Victoria, 3010, Australia.
Justin WongThe University of Sydney, School of Medical Sciences, Sydney, New South Wales, 2006, Australia.ORCID 0000-0002-7038-5079
Quintin LeeThe University of Sydney, School of Medical Sciences, Sydney, New South Wales, 2006, Australia.
Alexey TerskikhHarry Perkins Institute of Medical Research, The University of Western Australia, Australia.
Martin Alvarez-KuglenHarry Perkins Institute of Medical Research, The University of Western Australia, Australia.
Tara KarnezisGertrude Biomedical Pty Ltd., Bio21, Melbourne, Victoria, Australia.
Thomas GüntherLeibniz Institute of Virology, Germany.
Adam GrundhoffLeibniz Institute of Virology, Germany.
Biswajyoti SahuApplied Tumor Genomics Research Program, University of Helsinki, Finland.
Mathias FrancoísThe University of Sydney, School of Medical Sciences, Sydney, New South Wales, 2006, Australia.
Päivi M OjalaTranslational Cancer Medicine Research Program, University of Helsinki, Finland.

Funding

Blood vessel assembly from multipotent hemangioma-derived stem cellsR01HL096384 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Joyce E. Bischoff · 2009 to 2026
$7.7M
NHLBI NIH HHS R01 HL096384
6 · The paper itself

Abstract

Kaposi's sarcoma herpesvirus (KSHV) establishes lifelong oncogenic infection in lymphatic endothelial cells (LECs) by ensuring episomal maintenance of its genome via the viral protein LANA. Efficient viral genome maintenance typically involves host DNA replication and episome tethering, but the extent of cell-type-specific regulation remains unclear. Here, we identify that KSHV hijacks the pioneering function of the endothelial-specific transcription factor SOX18 to facilitate persistence of viral episomes. Upon infection, LANA co-opts SOX18 to recruit the SWI/SNF chromatin-remodeling complex via its ATPase subunit BRG1, enhancing chromatin accessibility and enabling efficient viral genome persistence. Disruption of SOX18 or BRG1-genetically or pharmacologically-leads to reduced episome load and attenuated hallmarks of virus infection. This work highlights how viruses can harness lineage-specific transcriptional regulators to establish persistent nuclear retention of their episome into the host genome.

Indexed as

BRG1chromatinendothelial cellherpesvirusKSHVpioneersmall molecule inhibitorSOX18Transcription factor

Identifiers

PMID40894008
PMCPMC12393484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.